Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Update on the treatment of ankylosing spondylitis

Authors Walter P Maksymowych

Published 15 January 2008 Volume 2007:3(6) Pages 1125—1133

Walter P Maksymowych
Heritage Medical Research Building, University of Alberta, Edmonton, Alberta, Canada
Abstract: Non-steroidal anti-inflammatory agents (NSAIDs) remain the mainstay of treatment for ankylosing spondylitis (AS) though one recent trial suggests that continuous as opposed to on-demand use may be superior in preventing progression of structural damage. One particular NSAID, which is a highly selective cyclo-oxygenase 2 inhibitor, etoricoxib, may be superior to standard NSAIDs for AS. Second-line agents typically used for rheumatoid arthritis appear to lack efficacy. Salazopyrin is only moderately effective in the subgroup of AS patients with concomitant peripheral arthritis and not in those with purely axial disease. A recent trial showed that there is no greater efficacy in patients presenting early in their disease course. Three anti-tumor necrosis factor alpha agents, infliximab, etanercept, and adalimumab, are now available for the treatment of AS, the latest being adalimumab. All possess similar clinical efficacy in phase III trials with response rates of about 60%. Imaging studies using magnetic resonance show substantial amelioration of inflammatory lesions in the spine and sacroiliac joints. There is as yet no evidence that any of these agents prevent progression of structural damage. One study that evaluated etanercept demonstrated no impact on damage progression. Increasing evidence points to the superiority of the two monoclonal antibodies, infliximab and adalimumab, over etanercept for the treatment of extra-articular manifestations typically seen in AS such as acute anterior uveitis and inflammatory bowel disease. All three agents can be used as monotherapy and concomitant methotrexate appears to offer no advantages although insufficient doses have been used to date. Future studies should target patients earlier in their disease course as well as those with adverse prognostic factors such as elevated serum metalloproteinase 3 levels and radiographic evidence of spinal ankylosis.
Keywords: infliximab, etanercept, adalimumab, ankylosing spondylitis, NSAIDs

Download Article [PDF] 

Readers of this article also read:

Imaging of pulmonary emphysema: A pictorial review

Masashi Takahashi, Junya Fukuoka, Norihisa Nitta, Ryutaro Takazakura, Yukihiro Nagatani, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:193-204

Published Date: 6 June 2008

Managing anemia in lymphoma and multiple myeloma

Gunnar Birgegård

Therapeutics and Clinical Risk Management 2008, 4:527-539

Published Date: 11 April 2008

Treatment of non-alcoholic fatty liver disease

Keith G Tolman, Anthony S Dalpiaz

Therapeutics and Clinical Risk Management 2007, 3:1153-1163

Published Date: 15 January 2008

Pharmacological causes of hyperprolactinemia

Daria La Torre, Alberto Falorni

Therapeutics and Clinical Risk Management 2007, 3:929-951

Published Date: 15 November 2007

RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker ανβ3 integrin with MR T1 mapping

Tianyi Ke, Eun-Kee Jeong, Xuli Wang, Yi Feng, Dennis L Parker, Zheng-Rong Lu

International Journal of Nanomedicine 2007, 2:191-199

Published Date: 15 July 2007

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007

Effect of patient-specific factors on weekly warfarin dose

Heather P Whitley, Joli D Fermo, Elinor CG Chumney, Walter Adam Brzezinski

Therapeutics and Clinical Risk Management 2007, 3:499-504

Published Date: 15 July 2007